The latest reports on biomarkers used in the diagnosis of ovarian cancer
DOI:
https://doi.org/10.12775/JEHS.2022.12.07.080Keywords
biomarkers, ovarian cancer, advanceAbstract
Introduction: Ovarian cancer ranks seventh in terms of incidence and eighth in terms of mortality among women worldwide. It is divided into several subtypes. The epithelial type of ovarian cancer is responsible for 90% of cases. The clinical picture is usually an appendage tumor detected by palpation or during pelvic imaging. Symptoms are usually non-specific such as abdominal pushing or bloating.
State of knowledge: Ovarian cancer is usually detected at an advanced stage due to the long duration of absence of symptoms. Therefore, there is an urgent need to look at existing and identify potential biomarkers that can lead to the development of new and more effective predictors for the diagnosis and prognosis of ovarian cancer. The ability of these biomarkers to predict the existence and stages of ovarian cancer could improve early diagnosis and survival of ovarian cancer patients. Currently, the biomarkers CA-125 and HE4 play the most important role in diagnosis. However, there are an increasing number of reports on other biomarkers such as kallikreins, bikunin, VEGF, and mesothelin.
Summary: Partly due to the lack of effective screening, ovarian cancer is usually diagnosed in the final stages. This is why ongoing research into new biomarkers that could contribute to faster detection of the disease is so important. They would also increase the effectiveness of the therapies used and enable a better prognosis of the course of the disease.
References
Momenimovahed Z, Tiznobaik A, Taheri S, et al. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health 2019;11:287-99
Braveman P, Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep 2014;129:19-31.
Patni R. Screening for Ovarian Cancer: An Update. J Midlife Health 2019;10:3-5.
https://www.onkonet.pl/dp_nnr_rak_jajnika.php#menu6
Arend R, Martinez A, Szul T, Birrer MJ. Biomarkers in ovarian cancer: To be or not to be. Cancer. 2019 Dec 15;125 Suppl 24:4563-4572. doi: 10.1002/cncr.32595. PMID: 31967683.
Boyd J. Specific Keynote: Hereditary Ovarian Cancer: What We Know. Gynecol Oncol 2003;88:S8-10.
Singla A. Epidemiology and Risk Factors for Ovarian Cancer. In: Preventive Oncology for the Gynecologist. Singapore: Springer Singapore, 2019:223-31.
Goff BA, Mandel L, Muntz HG, et al. Ovarian carcinoma diagnosis. Cancer 2000;89:2068-75.
Olson SH, Mignone L, Nakraseive C, et al. Symptoms of ovarian cancer. Obstet Gynecol 2001;98:212-7.
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019 Mar 27;12(1):28. doi: 10.1186/s13048-019-0503-7. PMID: 30917847; PMCID: PMC6436208.
Radu MR, Prădatu A, Duică F, Micu R, Creţoiu SM, Suciu N, Creţoiu D, Varlas VN, Rădoi VE. Ovarian Cancer: Biomarkers and Targeted Therapy. Biomedicines. 2021 Jun 18;9(6):693. doi: 10.3390/biomedicines9060693. PMID: 34207450; PMCID: PMC8235073.
Roberto Scatena: Advances in Cancer Biomarkers: From biochemistry to clinic for a critical revision. Springer, 2015. ISBN 978-94-017-7215-0.
Bast RC, Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68:1331–1337. doi: 10.1172/JCI110380.
Chen X, Zhou H, Chen R, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clin Chim Acta. 2014;440C:57–63.
Markman The role of CA-125 in the Management of Ovarian Cancer. Oncologist. 1997;2:6–9.
Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–265. doi: 10.1002/1096-9098(200012)75:4<264::AID-JSO7>3.0.CO;2-Q.
Hirsch M, Duffy J, Davis CJ, et al. Diagnostic accuracy of cancer antigen 125 for endometriosis: a systematic review and meta-analysis. BJOG. 2016;123:1761–1768. doi: 10.1111/1471-0528.14055.
Dehaghani AS, Ghiam AF, Hosseini M, et al. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women. Pathol Oncol Res. 2007;13:360–364. doi: 10.1007/BF02940317.
Lowe KA, Shah C, Wallace E, et al. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomark Prev. 2008;17:2480–2487. doi: 10.1158/1055-9965.EPI-08-0150.
Ferraro S, Borille S, Caruso S, et al. Body mass index does not influence human epididymis protein 4 concentrations in serum. Clin Chim Acta. 2015;446:163–164. doi: 10.1016/j.cca.2015.04.028.
Merlo S, Besic N, Drmota E, Kovacevic N. Preoperative serum CA-125 level as a predictor for the extent of cytoreduction in patients with advanced stage epithelial ovarian cancer. Radiol Oncol. 2021 Aug 10;55(3):341-346. doi: 10.2478/raon-2021-0013. PMID: 33675192; PMCID: PMC8366730.
Vorgias G, Iavazzo C, Savvopoulos P, Myriokefalitaki E, Katsoulis M, Kalinoglou N. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol. 2009;112:11–5. doi: 10.1016/j.ygyno.2008.09.020. et al. doi.
Arab M, Jamdar F, Sadat Hosseini M, Ghodssi-Ghasemabadi R, Farzaneh F, Ashrafganjoie T. Model for prediction of optimal debulking of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2018;19:1319–24. doi: 10.22034/APJCP.2018.19.5.1319. doi.
Bouchard D, Morisset D, Bourbonnais Y, Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 2006;7:167–174. doi: 10.1016/S1470-2045(06)70579-4.
Jing J, Gao Y. Urine biomarkers in the early stages of diseases: current status and perspective. Discov Med 2018;25:57-65.
Lu R, Sun X, Xiao R, et al. Human epididymis protein 4 (HE4) plays a key role in ovarian cancer cell adhesion and motility. Biochem Biophys Res Commun 2012;419:274-80. 10.1016/j.bbrc.2012.02.008.
Lakshmanan M, Kumar V, Chaturvedi A, et al. Role of serum HE4 as a prognostic marker in carcinoma of the ovary. Indian J Cancer 2019;56:216-21. 10.4103/ijc.IJC_305_18.
Liao JB, Yip YY, Swisher EM, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecol Oncol 2015;137:430-5. 10.1016/j.ygyno.2015.03.044
Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–1319. doi: 10.1038/sj.bjc.6605011.
Bolstad N, Øijordsbakken M, Nustad K, Bjerner J. Human epididymis protein 4 reference limits and natural variation in a Nordic reference population. Tumour Biol. 2012;33:141–148. doi: 10.1007/s13277-011-0256-4.
Ferraro S, Borille S, Caruso S, et al. Body mass index does not influence human epididymis protein 4 concentrations in serum. Clin Chim Acta. 2015;446:163–164. doi: 10.1016/j.cca.2015.04.028.
Urban N, Thorpe J, Karlan BY, et al. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer. Cancer Epidemiol Biomark Prev. 2012;21:2087–2094. doi: 10.1158/1055-9965.EPI-12-0616.
Ferraro S, Schiumarini D, Panteghini M. Human epididymis protein 4: factors of variation. Clin Chim Acta. 2015;438:171–177. doi: 10.1016/j.cca.2014.08.020.
Schmitt M, Magdolen V. Using kallikrein-related peptidases (KLK) as novel cancer biomarkers. Thromb Haemost. 2009;101:222–224.
Dorn J, Harbeck N, Kates R, Gkazepis A, Scorilas A, Soosaipillai A, Diamandis E, Kiechle M, Schmalfeldt B, Schmitt M. Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer. Ann Oncol. 2010;22:877–883.
Diamandis EP, Yousef GM, Soosaipillai AR, Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin Biochem. 2000;33:579–583.
Shih Ie M, Salani R, Fiegl M, Wang TL, Soosaipillai A, Marth C, Muller-Holzner E, Gastl G, Zhang Z, Diamandis EP. Ovarian cancer specific kallikrein profile in effusions. Gynecol Oncol. 2007;105:501–507.
Chen E, Zhu H, Yang Y, Wang L, Zhang J, Han Y, Liu X. Analysis of expression and prognosis of KLK7 in ovarian cancer. Open Med (Wars). 2020 Sep 30;15(1):932-939. doi: 10.1515/med-2020-0139. PMID: 33336051; PMCID: PMC7712299.
Kyriakopoulou LG, Yousef GM, Scorilas A, Katsaros D, Massobrio M, Fracchioli S, et al. Prognostic value of quantitatively assessed klk7 expression in ovarian cancer. Clin Biochem. 2003;36:135–43.
Ramani VC, Haun RS. The extracellular matrix protein fibronectin is a substrate for kallikrein 7. Biochem Biophys Res Commun. 2008;369:1169–1173. doi: 10.1016/j.bbrc.2008.03.021.
Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Suzuki M, Yamakawa T, Morishita H, Terao T. Reduced bikunin gene expression as a factor of poor prognosis in ovarian carcinoma. Cancer. 2003 Jul 15;98(2):424-30. doi: 10.1002/cncr.11506. PMID: 12872365.
Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF. In: Madame Curie Bioscience Database [Internet].
Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9:669-76.
Dobrzycka B, Mackowiak-Matejczyk B, Terlikowska KM, Kulesza-Bronczyk B, Kinalski M, Terlikowski SJ. Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma. Tumor Biol. 2015; 36:4157-65.
Cheng D, Liang B, Li Y. Serum vascular endothelial growth factor (VEGF-C) as a diagnostic and prognostic marker in patients with ovarian cancer. PLoS One. 2013;8: e55309.
Chaplain MA, McDougall SR, Anderson AR. Mathematical modeling of tumor-induced angiogenesis. Annu Rev Biomed Eng. 2006; 8:233-57.
Sopo M, Anttila M, Hämäläinen K, Kivelä A, Ylä-Herttuala S, Kosma VM, Keski-Nisula L, Sallinen H. Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer. BMC Cancer. 2019 Jun 14;19(1):584. doi: 10.1186/s12885-019-5757-3. PMID: 31200683; PMCID: PMC6570919.
Orre M, Rogers PA. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer. 1999;84(2):101–108. doi: 10.1002/(SICI)1097-0215(19990420)84:2<101::AID-IJC2>3.0.CO;2-5.
Nishida N, Yano H, Komai K, Nishida T, Kamura T, Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer. 2004;101(6):1364–1374. doi: 10.1002/cncr.20449.
Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, Emoto M, Umemoto M, Sakamoto T, Sato S, Mizunuma H, Smith SK. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88(2):237–244. doi: 10.1038/sj.bjc.6600701.
Shen GH, Ghazizadeh M, Kawanami O, Shimizu H, Jin E, Araki T, Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83(2):196–203. doi: 10.1054/bjoc.2000.1228.
Nakamura Y, Yasuoka H, Tsujimoto M, Imabun S, Nakahara M, Nakao K, et al. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast cancer research and treatment. 2005;91(2):125–32. doi: 10.1007/s10549-004-5783-x
Ding Y, Oliveira-Ferrer L, Vettorazzi E, Legler K, Milde-Langosch K, Woelber L, Jaeger A, Prieske K, Mueller V, Schmalfeldt B, Kuerti S. VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients. PLoS One. 2022 Jun 10;17(6):e0269680. doi: 10.1371/journal.pone.0269680. PMID: 35687576; PMCID: PMC9187059.
Chang K., Pastan I., Willingham M.C. Isolation and characterization of a monoclonal antibody, k1, reactive with ovarian cancers and normal mesothelium. Int. J. Cancer. 1992;50:373–381. doi: 10.1002/ijc.2910500308.
Pastan I., Zhang Y. Modulating mesothelin shedding to improve therapy. Oncotarget. 2012;3:114–115. doi: 10.18632/oncotarget.445.
Hassan R., Bera T., Pastan I. Mesothelin: A new target for immunotherapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004;10:3937–3942. doi: 10.1158/1078-0432.CCR-03-0801.
Cheng WF, Huang CY, Chang MC, Hu YH, Chiang YC, Chen YL, et al. High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma. Br J Cancer. (2009) 100:1144–53. 10.1038/sj.bjc.6604964
Hassan R, Kreitman RJ, Pastan I, Willingham MC. Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol. (2005) 13:243–7. 10.1097/01.pai.00000141545.36485.d6
Wu X., Li D., Liu L., Liu B., Liang H., Yang B. Serum soluble mesothelin-related peptide (SMRP): A potential diagnostic and monitoring marker for epithelial ovarian cancer. Arch. Gynecol. Obstet. 2014;289:1309–1314. doi: 10.1007/s00404-013-3128-x.
Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, et al. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol. (2007) 106:490–7. 10.1016/j.ygyno.2007.04.022.
Hollevoet K., Speeckaert M.M., Decavele A.S., Vanholder R., van Meerbeeck J.P., Delanghe J.R. Mesothelin levels in urine are affected by glomerular leakage and tubular reabsorption. Clin. Lung Cancer. 2012;13:470–474. doi: 10.1016/j.cllc.2011.12.004.
Chang MC, Chen CA, Hsieh CY, Lee CN, Su YN, Hu YH, et al. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. Biochem J. (2009) 424:449–58. 10.1042/BJ20082196.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Aleksandra Chałupnik, Zuzanna Chilimoniuk, Maciej Dobosz, Anna Sobstyl, Małgorzata Sobstyl
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 391
Number of citations: 0
